Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.34 |
| ▸ | SLC9A3 | P48764 | 10/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874559 | 0.94 | NPY4R (0.36) | SLC9A3 | |
| SCHEMBL1799060 | 0.93 | SLC9A3 (0.36) | SLC9A3 | |
| SCHEMBL1800587 | 0.93 | SLC9A3 (0.33) | SLC9A3CA12CA1CA2CA9 | |
| SCHEMBL4293042 | 0.93 | LTA4H (0.33) | SLC9A3CA12CA1CA2CA9 | |
| SCHEMBL4377327 | 0.90 | F2 (0.39) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL4370906 | 0.89 | SCN9A (0.36) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL4372334 | 0.88 | LTA4H (0.40) | — | |
| SCHEMBL1800732 | 0.86 | MAP2K1 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL3875819 | 0.84 | SLC9A3 (0.41) | SLC9A3CA12CA1CA2CA9 | |
| SCHEMBL1800832 | 0.83 | F2 (0.37) | F2PRSS1PRSS2PRSS3ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | claimed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | F2 2817/4885PRSS1 198/4885PRSS2 511/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | F2 3029/4885PRSS1 40/4885PRSS2 148/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | F2 2803/4885PRSS1 322/4885PRSS2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.